ClinicalTrials.gg
Not yet recruitingNCT07888075REACHUpdated Oct 28, 2026

Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC

A Phase 2/3 interventional study of Rilogrotug and Placebo in Cachexia; Cancer, Cachexia and Cachexia-Anorexia Syndrome, sponsored by AVEO Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AVEO Pharmaceuticals, Inc. (part of LG Chem) · Phase 2/3, Interventional, and Treatment

Updated Oct 28, 2026Start date movedPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
950
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm). Adult participants with cachexia who have also been diagnosed with metastatic colorectal or non-small cell lung cancer will be enrolled.

The primary hypothesis is that after 12 weeks, rilogrotug will cause an increase from baseline in body weight and appetite (as measured by the Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale [FAACT-5IASS] questionnaire) compared to placebo.

Read the detailed description

This multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study is designed to compare the efficacy and safety of rilogrotug to a control arm of placebo for treatment of weight loss and anorexia in participants with cachexia who have also been diagnosed with metastatic colorectal cancer (mCRC) or metastatic non-small cell lung cancer (mNSCLC) and are receiving first line anticancer standard of care. The master protocol is designed with 4 sub-studies:

The Phase 2 (A) sub-study is designed to compare the efficacy and safety of two dose levels of rilogrotug (Arm 1 or Arm 2) to a control arm of placebo (Arm 3) in a 1:1:1 allocation. It is anticipated that the sub-study will enroll approximately 150 participants across 3 arms.

The Phase 3 (B) sub-study is designed to assess safety and efficacy of the selected optimal dose versus placebo in patients with cancer cachexia and mCRC in a 1:1 allocation. It is anticipated that the sub-study will enroll approximately 400 participants across 2 arms.

The Phase 3 (C) sub-study is designed to assess safety and efficacy of the selected optimal dose versus placebo in patients with cancer cachexia and mNSCLC in a 1:1 allocation. It is anticipated that the sub-study will enroll approximately 400 participants across 2 arms.

The OLE (D) sub-study is designed to allow participants who have completed one of the parent sub-studies (A), (B), (C) to continue receiving rilogrotug for up to an additional 12 months.

02

Conditions studied

  • Cachexia; Cancer
  • Cachexia
  • Cachexia-Anorexia Syndrome
  • Metastatic Colorectal Cancer (CRC)
  • Metastatic Non-small Cell Lung Cancer (NSCLC)
  • Weight Loss
  • Anorexia
03

In context

Cachexia

331 studies on the registry are indexed under Cachexia; 74 are open to participants now.

This study's planned enrollment of 950 is above the median of 74 across 226 interventional studies indexed under Cachexia.

Browse Cachexia studies →

Lead sponsor

AVEO Pharmaceuticals, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.

First submitted after AVEO Pharmaceuticals, Inc. became part of LG Chem.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Phase 2 (A), Phase 3 (B) \& (C) Inclusion Criteria (IC):

  • Documented histological or cytological confirmation of either mNSCLC or mCRC
  • For patients with mNSCLC, receiving (1L) systemic anticancer standard of care (SOC) treatment with standard approved regimens: the 1L systemic anticancer SOC treatments are a platinum-based doublet chemotherapy regimen, and an anti-PD-(L)1 immunotherapy
  • For patients with mCRC, receiving 1L systemic anticancer SOC treatment with standard approved regimens: fluorouracil-based regimens including oxaliplatin or irinotecan with or without biologics)
  • Documentation of by the patient or the patient's legally acceptable representative, indicating that the patient has been informed of and comprehended all pertinent aspects of the trial
  • Is willing and able to comply with the protocol tests and procedures
  • Age ≥18 years
  • Cachexia as defined by Fearon criteria for body weight and (BMI) (Fearon 2011)
  • ≥4months
  • performance status 0 to 2

Phase 2 (A), Phase 3 (B) \& (C) Exclusion Criteria (EC):

  • Anorexia or cachexia caused by reasons other than cancer (for example, severe [COPD] with home oxygen support)
  • Reversible causes of reduced food intake, as determined by the Investigator.
  • Dysphagia, calorie-restricted diet within 6 months prior to first dose, or poor food digestion and absorption
  • Currently receiving tube feedings or parenteral nutrition (either total or partial)
  • Have received medications and/or herbal supplements to enhance appetite and/or intended to treat unintentional weight loss
  • Patients with uncontrolled or significant cardiovascular disease
  • recurrent ascites, pleural effusion, pericardial effusion and or significant edema
  • ≤30 mL/min (measured or calculated by Cockcroft and Gault equation)
  • or alanine aminotransferase >5 × the (ULN) OR total >2 × ULN
  • Alkaline phosphatase (ALP) >3 x ULN (ALP >5× ULN if there is liver involvement by the tumor and/or in case of bone )

OLE (D) IC:

  • The patient completed double-blind treatment period
  • The patient expressed interest in participating in the optional OLE sub-study and provided a signed informed consent form specific to the OLE.
  • In the opinion of the Investigator, the patient continues to derive clinical benefit from study treatment, has not experienced any intolerable treatment-related toxicity of National Cancer Institute - (NCI CTCAE) Version 6.0 Grade ≥ 2

OLE (D) EC:

  • None
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
950 participants (estimated)

Study arms

  • Experimental
    Rilogrotug - high dose

    intravenous (IV) administration

    Biological: Rilogrotug

  • Experimental
    Rilogrotug - low dose

    IV administration

    Biological: Rilogrotug

  • Placebo comparator
    Placebo

    IV administration

    Biological: Placebo

Interventions

  • BiologicalRilogrotug

    Rilogrotug (AV-380) is a humanized immunoglobulin G1 kappa monoclonal antibody that binds to growth differentiation factor-15 (GDF-15).

  • BiologicalPlacebo

    Placebo for this study will be normal saline.

06

What researchers measure

Primary outcomes

  1. Phase 2 (A): To evaluate the effect of rilogrotug compared to placebo on weight gain

    Percent change from baseline in body weight

    Time frame: 12 weeks

  2. Phase 2 (A): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score

    Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome.

    Time frame: 12 weeks

  3. Phase 3 (B): To evaluate the effect of rilogrotug compared to placebo on weight gain

    Percent change from baseline in body weight

    Time frame: 12 weeks

  4. Phase 3 (B): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score

    Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome.

    Time frame: 12 weeks

  5. Phase 3 (C): To evaluate the effect of rilogrotug compared to placebo on weight gain

    Percent change from baseline in body weight

    Time frame: 12 weeks

  6. Phase 3 (C): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score

    Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome.

    Time frame: 12 weeks

  7. OLE (D): To evaluate the safety and tolerability of long-term rilogrotug administration

    Adverse events and Laboratory abnormalities

    Time frame: 52 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Mar 2030, 40 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Feb 2027 → Nov 2026, primary completion Oct 2028 → Mar 2030 and completion Jan 2031 → Oct 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2026
First posted
Oct 22, 2026
StartEst.
Nov 2026was Feb 2027
Primary completionEst.
Mar 2030was Oct 2028
CompletionEst.
Oct 2031was Jan 2031
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 2027→Nov 2026
Oct 28, 2026
Primary completion
Oct 2028→Mar 2030
Oct 28, 2026
Study completion
Jan 2031→Oct 2031
Oct 28, 2026
Enrollment
400→950
Oct 28, 2026
Eligibility
Criteria largely rewritten (25 changes)
What changed in the criteria
  • RemovedInclusion Criteria:
  • AddedPhase 2 (A), Phase 3 (B) \& (C) Inclusion Criteria (IC):
  • AddedDocumented histological or cytological confirmation of either mNSCLC or mCRC
  • AddedFor patients with mNSCLC, receiving first line (1L) systemic anticancer standard of care (SOC) treatment with standard approved regimens: the 1L systemic anticancer SOC treatments are a platinum-based doublet chemotherapy regimen, and an anti-PD-(L)1 immunotherapy
  • AddedFor patients with mCRC, receiving 1L systemic anticancer SOC treatment with standard approved regimens: fluorouracil-based regimens including oxaliplatin or irinotecan with or without biologics)
  • AddedDocumentation of informed consent by the patient or the patient's legally acceptable representative, indicating that the patient has been informed of and comprehended all pertinent aspects of the trial
  • AddedIs willing and able to comply with the protocol tests and procedures
  • AddedAge ≥18 years
  • AddedCachexia as defined by Fearon criteria for body weight and body mass index (BMI) (Fearon 2011)
  • AddedLife expectancy ≥4months
  • AddedEastern Cooperative Oncology Group performance status 0 to 2
  • AddedPhase 2 (A), Phase 3 (B) \& (C) Exclusion Criteria (EC):
  • AddedAnorexia or cachexia caused by reasons other than cancer (for example, severe chronic obstructive pulmonary disease [COPD] with home oxygen support)
  • AddedReversible causes of reduced food intake, as determined by the Investigator.
  • AddedDysphagia, calorie-restricted diet within 6 months prior to first dose, or poor food digestion and absorption
  • AddedCurrently receiving tube feedings or parenteral nutrition (either total or partial)
  • AddedHave received medications and/or herbal supplements to enhance appetite and/or intended to treat unintentional weight loss
  • AddedPatients with uncontrolled or significant cardiovascular disease
  • AddedClinically significant recurrent ascites, pleural effusion, pericardial effusion and or significant edema
  • AddedCreatinine clearance ≤30 mL/min (measured or calculated by Cockcroft and Gault equation)
  • AddedAspartate aminotransferase or alanine aminotransferase >5 × the upper limit of normal (ULN) OR total bilirubin >2 × ULN
  • AddedAlkaline phosphatase (ALP) >3 x ULN (ALP >5× ULN if there is liver involvement by the tumor and/or in case of bone metastases)
  • AddedOLE (D) IC:
  • AddedOLE (D) EC:
  • AddedNone
Oct 28, 2026
Interventions
Added Biological: Placebo. Arm changed Rilogrotug - Phase 2 dose→Rilogrotug - high dose; Rilogrotug - Phase 3 dose→Rilogrotug - low dose. Arms added: Placebo
Oct 28, 2026
Primary outcomes
1 edited, 6 added
What changed in the outcomes
  • EditedOLE (D): To evaluate the safety and tolerability of long-term rilogrotug administrationTime frame: 26 weeks → 52 weeks
  • AddedPhase 2 (A): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
  • AddedPhase 2 (A): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
  • AddedPhase 3 (B): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
  • AddedPhase 3 (B): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
  • AddedPhase 3 (C): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
  • AddedPhase 3 (C): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
Oct 28, 2026
Secondary outcomes
1 removed
What changed in the outcomes
  • RemovedTo evaluate the long-term effect of rilogrotug on body weightTime frame: From enrollment to 26 weeks
Oct 28, 2026
Title
OLE Study Subsequent to ParentMaster Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
Oct 28, 2026
Registered
First appeared on the registry
Oct 22, 2026
Show all 2 updates
  1. Oct 28, 2026
    Start date Feb 2027→Nov 2026
    Primary completion Oct 2028→Mar 2030
    Study completion Jan 2031→Oct 2031
    Enrollment 400→950
    Eligibility Criteria largely rewritten (25 changes)
    What changed in the criteria
    • RemovedInclusion Criteria:
    • AddedPhase 2 (A), Phase 3 (B) \& (C) Inclusion Criteria (IC):
    • AddedDocumented histological or cytological confirmation of either mNSCLC or mCRC
    • AddedFor patients with mNSCLC, receiving first line (1L) systemic anticancer standard of care (SOC) treatment with standard approved regimens: the 1L systemic anticancer SOC treatments are a platinum-based doublet chemotherapy regimen, and an anti-PD-(L)1 immunotherapy
    • AddedFor patients with mCRC, receiving 1L systemic anticancer SOC treatment with standard approved regimens: fluorouracil-based regimens including oxaliplatin or irinotecan with or without biologics)
    • AddedDocumentation of informed consent by the patient or the patient's legally acceptable representative, indicating that the patient has been informed of and comprehended all pertinent aspects of the trial
    • AddedIs willing and able to comply with the protocol tests and procedures
    • AddedAge ≥18 years
    • AddedCachexia as defined by Fearon criteria for body weight and body mass index (BMI) (Fearon 2011)
    • AddedLife expectancy ≥4months
    • AddedEastern Cooperative Oncology Group performance status 0 to 2
    • AddedPhase 2 (A), Phase 3 (B) \& (C) Exclusion Criteria (EC):
    • AddedAnorexia or cachexia caused by reasons other than cancer (for example, severe chronic obstructive pulmonary disease [COPD] with home oxygen support)
    • AddedReversible causes of reduced food intake, as determined by the Investigator.
    • AddedDysphagia, calorie-restricted diet within 6 months prior to first dose, or poor food digestion and absorption
    • AddedCurrently receiving tube feedings or parenteral nutrition (either total or partial)
    • AddedHave received medications and/or herbal supplements to enhance appetite and/or intended to treat unintentional weight loss
    • AddedPatients with uncontrolled or significant cardiovascular disease
    • AddedClinically significant recurrent ascites, pleural effusion, pericardial effusion and or significant edema
    • AddedCreatinine clearance ≤30 mL/min (measured or calculated by Cockcroft and Gault equation)
    • AddedAspartate aminotransferase or alanine aminotransferase >5 × the upper limit of normal (ULN) OR total bilirubin >2 × ULN
    • AddedAlkaline phosphatase (ALP) >3 x ULN (ALP >5× ULN if there is liver involvement by the tumor and/or in case of bone metastases)
    • AddedOLE (D) IC:
    • AddedOLE (D) EC:
    • AddedNone
    Primary outcomes 1 edited, 6 added
    What changed in the outcomes
    • EditedOLE (D): To evaluate the safety and tolerability of long-term rilogrotug administrationTime frame: 26 weeks → 52 weeks
    • AddedPhase 2 (A): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
    • AddedPhase 2 (A): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
    • AddedPhase 3 (B): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
    • AddedPhase 3 (B): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
    • AddedPhase 3 (C): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
    • AddedPhase 3 (C): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
    Secondary outcomes 1 removed
    What changed in the outcomes
    • RemovedTo evaluate the long-term effect of rilogrotug on body weightTime frame: From enrollment to 26 weeks
    Interventions Added Biological: Placebo. Arm changed Rilogrotug - Phase 2 dose→Rilogrotug - high dose; Rilogrotug - Phase 3 dose→Rilogrotug - low dose. Arms added: Placebo
    Title OLE Study Subsequent to ParentMaster Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC
    + 3 other changes: verification date, description and design details
  2. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07888075
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Nov 2026 (estimated)
Primary completion
Mar 2030 (estimated)
Completion
Oct 2031 (estimated)
Last update
Oct 28, 2026

Study contacts

Clinical Trial Office
Contact
clinical@aveooncology.com
+1-854-400-0101

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilogrotug

Start the discussion